Jagsonpal Pharmaceuticals507789Acquisition deal news
Jagsonpal completes acquisition of Group Pharmaceuticals' wellness portfolio; ~₹23.7 Cr upfront plus up to ~₹23.0 Cr deferred
50%Share of consideration structured as deferred payments
- Upfront Consideration
- ~₹23.7 Cr upfront consideration plus ~₹23.0 Cr maximum additional consideration linked to FY28 sales
- Effective Date
- with effect from October 01, 2026
- Target FY26 Revenue
- FY26 revenue ~₹24.6 Cr
- Key Brands
- brands Hemozink and Sudin
- SKU Count
- ~6 SKUs
Jagsonpal completes acquisition of Group Pharmaceuticals' wellness portfolio; ~₹23.7 Cr upfront plus up to ~₹23.0 Cr deferred.
Intimation of Business Transfer Agreement prior intimation of BTA signing
Transaction consummated with effect from today
More numbers
- Upfront consideration~₹23.7 Cr
- Maximum additional consideration linked to FY28 sales~₹23.0 Cr
- FY26 revenue of the wellness portfolio~₹24.6 Cr
- Share of consideration structured as deferred paymentsalmost 50%
- FY26 gross margin of the wellness portfolio78.1%
- Doctors covered by Group Pharmaceuticals' portfolio~30,000
- Doctors covered by Jagsonpal54,000+
- States of presence of the wellness portfolio6
- Cash balance as of Q1FY27~₹170 Cr
- Cash reserves in excess ofRs. 100 crores
Source: BSE · 1 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.